Key result
Female sex was an independent predictor of functional class improvement in HFrEF patients treated with sacubitril/valsartan.
Why the study?
Women are underrepresented in sacubitril/valsartan clinical trials, leaving sex-specific differences in efficacy, tolerability, and safety unclear in real-world HFrEF patients.
Does female sex influence the efficacy, tolerability, and safety of sacubitril/valsartan in patients with HFrEF?
Observational (n=427)
Yes
Does female sex influence the efficacy, tolerability, and safety of sacubitril/valsartan in patients with HFrEF?
In real-world HFrEF patients, sacubitril/valsartan shows similar tolerability between sexes, but women may experience more frequent functional class improvement.
Answers are grounded in this paper and cite their sources.
May indicate greater functional response to sacubitril/valsartan in women with HFrEF; hypothesis-generating and requires RCT confirmation.
BACKGROUND: Women are underrepresented in sacubitril/valsartan (SV) clinical trials. The aim of this study was to assess sex-specific differences in efficacy, tolerability, and safety of SV in real-world heart failure with reduced ejection fraction (HFrEF) patients. METHODS: A prospective registry in 10 centers including all patients who started SV during the last 6 months was analyzed in this study. RESULTS: A total of 427 patients were included, 126 (29.5%) were women. There were no substantial differences in HFrEF treatment before SV initiation, although fewer women than men carried an implantable cardioverter defibrillator (57 [45.2%] vs. 173 [58.1%], p = 0.02). SV starting dose was 24/26 mg b.i.d. in 206 patients (48.2%), 49/51 mg b.i.d. in 184 (43.1%), and 97/103 mg b.i.d. in 34 (8.2%), without relevant differences associated to sex. There were no losses during a mean follow-up of 7.0 ± 0.1 months. The proportion of patients who discontinued the drug (16 [12.7%] women vs. 33 [11.0%] men, p = 0.66) or presented SV-related adverse effects (31 [24.6%] women vs. 79 [26.5%] men, p = 0.72) was also similar in both sexes. However, female sex was an independent predictor of functional class improvement in the multivariate analysis (odds ratio 2.33, 95% confidence interval: 1.24-4.38, p = 0.04). CONCLUSIONS: SV in women with HFrEF has a similar tolerability as in men. Females seem to have a more frequent functional class improvement than males.
No takes yet. Share an insight, caveat, or question.
Vicent et al. (2019) conducted an observational in heart failure with reduced ejection fraction (HFrEF) (n=427). Female sex vs. Male sex was evaluated on functional class improvement (OR 2.33, 95% CI 1.24-4.38, p=0.04). Female sex was an independent predictor of functional class improvement in HFrEF patients treated with sacubitril/valsartan.
Synapse has enriched 10 related papers. Consider them for comparative context: